

July 22, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400051.

Scrip Code / Symbol : **IPCALAB**

Sub: Report on Complaints in terms of Para 6 of Part I(A) of the SEBI Master Circular No. SEBI/HO/CFD/POD-2/CIR/2023/93 dated 20th June, 2023 ("SEBI Master Circular")

Ref: Application No. 56067 filed on June 30, 2026 under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations") for the Scheme of Arrangement between Krebs Biochemicals & Industries Limited ("Transferor Company") and Ipca Laboratories Limited ("Transferee Company") and their respective shareholders and creditors under Section 230 to 232 and section 66 of the Companies Act, 2013, and other applicable laws including the rules and regulations ("Scheme").

Dear Sir/Madam,

This is in reference to the Scheme filed by the Company with BSE Limited (BSE) under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Scheme of Arrangement between Krebs Biochemicals & Industries Limited and Ipca Laboratories Limited and their respective shareholders and creditors under Section 230 to 232 and section 66 of the Companies Act, 2013, and other applicable laws including the rules and regulations on June 30, 2026 vide Application number 56067 and subsequent hosting of the scheme along with other relevant documents by our Company on our website.

The period of 21 days from the date of filing of Draft Scheme with Stock Exchanges and uploading of the draft Scheme along with related documents on our website has expired on July 21, 2026.

It may be noted that the Company has not received any complaints with respect to the Scheme till date either directly or through BSE Limited (BSE) or National Stock Exchange of India Limited (NSE). In terms of Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. SEBI/HO/CFD/POD-2/CIR/2023/93 dated June 20, 2023, please find enclosed the Report on Complaints in the prescribed format as **Annexure-A**

Request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For Ipca Laboratories Limited



Harish P Kamath
Corporate Counsel & Company Secretary
End: As Above


Ipca Laboratories Ltd.
www.ipca.com

Annexure-A**REPORT ON COMPLAINTS****(Period: June 30, 2026 to July 21, 2026)****Part A**

Sr. No.	Particulars	Number
1.	Number of complaints received directly	Nil
2.	Number of complaints forwarded by Stock Exchanges/SEBI	Nil
3.	Total Number of complaints/comments received (1+2)	Nil
4.	Number of complaints resolved	Not Applicable
5.	Number of complaints pending	Not Applicable

Part B

Sr. No.	Name of complainant	Date of complaint	Status (Resolved/Pending)
Not Applicable			

For Ipca Laboratories Limited**Harish P Kamath**

Corporate Counsel & Company Secretary

Date: July 22, 2026

Ipca Laboratories Ltd.www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837